Cargando…

Toxicological Characterization of GHB as a Performance-Enhancing Drug

Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide d...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgetti, Arianna, Busardò, Francesco Paolo, Giorgetti, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058118/
https://www.ncbi.nlm.nih.gov/pubmed/35509886
http://dx.doi.org/10.3389/fpsyt.2022.846983
_version_ 1784698054002081792
author Giorgetti, Arianna
Busardò, Francesco Paolo
Giorgetti, Raffaele
author_facet Giorgetti, Arianna
Busardò, Francesco Paolo
Giorgetti, Raffaele
author_sort Giorgetti, Arianna
collection PubMed
description Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide diffusion in the bodybuilding community. The aim of the present work is to provide a toxicological characterization of the use of GHB as a PED, including the scientific basis for its use, the patterns of use/abuse, and the health risks arising from its consumption in this peculiar recreative setting. A literature search was performed on multiple databases including experimental studies on humans and animals as well as epidemiological reports and forensic case reports/series. Experimental studies demonstrated that the use of GHB as a PED is motivated by the release of growth hormone and the induction of sleep. However, the panel of desired performance-related effects was much wider in real cases and epidemiological studies. Even though the use of GHB among bodybuilders has decreased, its use to enhance some kind of performance, particularly sexual ones or social-communicative ones, as well as means to increase mood and perceived energy, is still common.
format Online
Article
Text
id pubmed-9058118
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90581182022-05-03 Toxicological Characterization of GHB as a Performance-Enhancing Drug Giorgetti, Arianna Busardò, Francesco Paolo Giorgetti, Raffaele Front Psychiatry Psychiatry Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide diffusion in the bodybuilding community. The aim of the present work is to provide a toxicological characterization of the use of GHB as a PED, including the scientific basis for its use, the patterns of use/abuse, and the health risks arising from its consumption in this peculiar recreative setting. A literature search was performed on multiple databases including experimental studies on humans and animals as well as epidemiological reports and forensic case reports/series. Experimental studies demonstrated that the use of GHB as a PED is motivated by the release of growth hormone and the induction of sleep. However, the panel of desired performance-related effects was much wider in real cases and epidemiological studies. Even though the use of GHB among bodybuilders has decreased, its use to enhance some kind of performance, particularly sexual ones or social-communicative ones, as well as means to increase mood and perceived energy, is still common. Frontiers Media S.A. 2022-04-18 /pmc/articles/PMC9058118/ /pubmed/35509886 http://dx.doi.org/10.3389/fpsyt.2022.846983 Text en Copyright © 2022 Giorgetti, Busardò and Giorgetti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Giorgetti, Arianna
Busardò, Francesco Paolo
Giorgetti, Raffaele
Toxicological Characterization of GHB as a Performance-Enhancing Drug
title Toxicological Characterization of GHB as a Performance-Enhancing Drug
title_full Toxicological Characterization of GHB as a Performance-Enhancing Drug
title_fullStr Toxicological Characterization of GHB as a Performance-Enhancing Drug
title_full_unstemmed Toxicological Characterization of GHB as a Performance-Enhancing Drug
title_short Toxicological Characterization of GHB as a Performance-Enhancing Drug
title_sort toxicological characterization of ghb as a performance-enhancing drug
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058118/
https://www.ncbi.nlm.nih.gov/pubmed/35509886
http://dx.doi.org/10.3389/fpsyt.2022.846983
work_keys_str_mv AT giorgettiarianna toxicologicalcharacterizationofghbasaperformanceenhancingdrug
AT busardofrancescopaolo toxicologicalcharacterizationofghbasaperformanceenhancingdrug
AT giorgettiraffaele toxicologicalcharacterizationofghbasaperformanceenhancingdrug